[go: up one dir, main page]

CO2018002545A2 - Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona - Google Patents

Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Info

Publication number
CO2018002545A2
CO2018002545A2 CONC2018/0002545A CO2018002545A CO2018002545A2 CO 2018002545 A2 CO2018002545 A2 CO 2018002545A2 CO 2018002545 A CO2018002545 A CO 2018002545A CO 2018002545 A2 CO2018002545 A2 CO 2018002545A2
Authority
CO
Colombia
Prior art keywords
quinazolin
piperidin
dione
oxo
amino
Prior art date
Application number
CONC2018/0002545A
Other languages
English (en)
Inventor
Daozhong Zou
Colin Walters
William Bowen
Yali Sun
Jay Brumfield
Xiaoxuan Shen
Indrajit Ghosh
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CO2018002545A2 publication Critical patent/CO2018002545A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)

Abstract

Se proveen en la presente las composiciones farmacéuticas y formas de dosificación unitarias de Compuesto A (3-(5-amino-2-metil-4-oxo-4H-quinazolin-3-il)-piperidin-2,6-diona), o un enantiómero o una mezcla de enantiómeros de este, un solvato, hidrato, cocristal, clatrato, polimorfo o sal farmacéuticamente aceptable de este. También se proveen métodos para tratar, controlar o prevenir el cáncer con las formas de dosificación descritas en la presente.
CONC2018/0002545A 2015-08-27 2018-03-09 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona CO2018002545A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562210923P 2015-08-27 2015-08-27
PCT/US2016/048905 WO2017035443A1 (en) 2015-08-27 2016-08-26 Pharmaceutical compositions comprising 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Publications (1)

Publication Number Publication Date
CO2018002545A2 true CO2018002545A2 (es) 2018-07-10

Family

ID=56883865

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0002545A CO2018002545A2 (es) 2015-08-27 2018-03-09 Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona

Country Status (17)

Country Link
US (1) US10064863B2 (es)
EP (1) EP3340969B1 (es)
JP (1) JP2018525422A (es)
KR (1) KR20180039084A (es)
CN (1) CN107921004A (es)
AU (1) AU2016310340A1 (es)
BR (1) BR112018003335A2 (es)
CA (1) CA2996641A1 (es)
CL (1) CL2018000489A1 (es)
CO (1) CO2018002545A2 (es)
EA (1) EA201890585A1 (es)
EC (1) ECSP18023544A (es)
ES (1) ES2865289T3 (es)
HK (1) HK1252415A1 (es)
IL (1) IL257666A (es)
MX (1) MX2018002487A (es)
WO (1) WO2017035443A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180023968A (ko) 2015-07-02 2018-03-07 셀진 코포레이션 혈액암 및 충실성 종양의 치료를 위한 병용 요법
WO2017096024A1 (en) 2015-12-02 2017-06-08 Celgene Corporation Cycling therapy using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
WO2021080937A1 (en) * 2019-10-21 2021-04-29 Celgene Corporation Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP3239144A1 (en) 2006-09-26 2017-11-01 Celgene Corporation 5-substituted quinazolinone derivatives as anti-cancer agents
US8802685B2 (en) * 2011-03-11 2014-08-12 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
BR112013023277A2 (pt) 2011-03-11 2017-06-27 Celgene Corp métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona
US20150196562A1 (en) 2014-01-15 2015-07-16 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione

Also Published As

Publication number Publication date
JP2018525422A (ja) 2018-09-06
ECSP18023544A (es) 2018-04-30
EA201890585A1 (ru) 2018-11-30
HK1252415A1 (zh) 2019-05-24
US10064863B2 (en) 2018-09-04
KR20180039084A (ko) 2018-04-17
IL257666A (en) 2018-04-30
EP3340969B1 (en) 2021-02-17
ES2865289T3 (es) 2021-10-15
US20170056323A1 (en) 2017-03-02
BR112018003335A2 (pt) 2018-09-25
MX2018002487A (es) 2018-06-15
EP3340969A1 (en) 2018-07-04
AU2016310340A1 (en) 2018-03-15
CL2018000489A1 (es) 2018-08-03
WO2017035443A1 (en) 2017-03-02
CA2996641A1 (en) 2017-03-02
CN107921004A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
EA201692436A1 (ru) Медицинское применение
PE20151005A1 (es) Composicion farmaceutica recubierta que contiene regorafenib
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
CO2018008305A2 (es) Formulaciones de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2020005145A (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil -etil]-4-acetilaminoisoindolin-1,3-diona.
MX2021005207A (es) Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-met ilciclohexilamino)-pirimidina-5-carboxamida.
MX2017007607A (es) Inhibidores de necrosis celular y metodos relacionados.
AR100663A1 (es) Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201691670A1 (ru) Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2
UY36123A (es) Derivados de carboxamida
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
CO2018002545A2 (es) Formulaciones de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
MX2019010108A (es) Derivados de azetidina.
MX386902B (es) Metodos para el tratamiento de trastornos cardiovasculares.
CU20160170A7 (es) Derivados de carboxamida
AR105923A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos